Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
Théroux P, Alexander J Jr, Pharand C, Barr E, Snapinn S, Ghannam AF, Sax FL. Théroux P, et al. Among authors: snapinn s. Circulation. 2000 Nov 14;102(20):2466-72. doi: 10.1161/01.cir.102.20.2466. Circulation. 2000. PMID: 11076818 Clinical Trial.
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.
Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Januzzi JL Jr, et al. Circulation. 2002 May 21;105(20):2361-6. doi: 10.1161/01.cir.0000016359.94919.16. Circulation. 2002. PMID: 12021221 Clinical Trial.
Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
Zhao XQ, Théroux P, Snapinn SM, Sax FL. Zhao XQ, et al. Among authors: snapinn sm. Circulation. 1999 Oct 12;100(15):1609-15. doi: 10.1161/01.cir.100.15.1609. Circulation. 1999. PMID: 10517731 Clinical Trial.
Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T, Theroux P, Snapinn S, Wan Y; Montreal General Hospital, Montreal, Quebec, Canada. thao.huynh@muhc.mcgill.ca. Huynh T, et al. Among authors: snapinn s. Am Heart J. 2003 Oct;146(4):668-73. doi: 10.1016/S0002-8703(03)00255-2. Am Heart J. 2003. PMID: 14564321 Clinical Trial.
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.
Mega JL, Morrow DA, Sabatine MS, Zhao XQ, Snapinn SM, DiBattiste PM, Gibson CM, Antman EM, Braunwald E, Théroux P. Mega JL, et al. Among authors: snapinn sm. Am Heart J. 2005 May;149(5):846-50. doi: 10.1016/j.ahj.2004.08.042. Am Heart J. 2005. PMID: 15894966
101 results